[99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT在前列腺癌中的临床性能:与[99mTc]Tc-MDP及PSMA PET/CT的头对头配对比较
单中心回顾性研究采用患者内配对扫描,比较[99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT与[99mTc]Tc-MDP(亚组A,n=38)及PSMA PET/CT(亚组B,n=13)在前列腺癌中的性能。亚组A中两者骨病灶灵敏度均高,但SPECT/CT特异性(100.0% vs 18.8%,P<0.001)和准确率(98.7% vs 82.9%,P<0.001)更高且假阳性更少。亚组B中病灶灵敏度相当(93.1% vs 96.6%,P=1.000),达到预设非劣效标准(Δ=10%)。
要点
- 与MDP相比,PSMA SPECT/CT骨病灶特异性更高且假阳性更少。
- 与PSMA PET/CT相比,病灶灵敏度相当并达到非劣效标准。
- 支持其作为可及性更佳的PSMA显像选择。
核心结论
- [99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT较[99mTc]Tc-MDP减少骨病灶假阳性,并与PSMA PET/CT达到预设非劣效标准。
研究设计与样本
- 单中心回顾性研究(2020年1月1日至2025年11月25日),采用30天内患者内配对扫描。
- 亚组A比较[99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT与[99mTc]Tc-MDP(n=38)。
- 亚组B比较[99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT与PSMA PET/CT([68Ga]Ga-PSMA-11或[18F]PSMA-1007,n=13)。
- 病灶以复合参考标准分类(Gold+/Gold−),灵敏度/特异性/准确率用McNemar检验比较。
- 对PET/CT的非劣效性采用Δ=10%(灵敏度和准确率)。
主要发现
- 亚组A评估76个骨病灶(Gold+60,Gold−16),MDP灵敏度100.0%,PSMA SPECT/CT灵敏度98.3%(P=1.000)。
- 亚组A中PSMA SPECT/CT特异性100.0%高于MDP的18.8%(P<0.001)。
- 亚组A中PSMA SPECT/CT准确率98.7%高于MDP的82.9%(P<0.001),假阳性分别为0和13。
- 亚组B总体病灶灵敏度93.1% vs 96.6%(P=1.000),达到非劣效标准(Δ=10%)。
- 亚组B特异性估计受Gold−病灶数量少限制。
关键数值与推荐
- 亚组A骨病灶灵敏度:MDP 100.0% vs PSMA SPECT/CT 98.3%(P=1.000)。
- 亚组A骨病灶特异性:PSMA SPECT/CT 100.0% vs MDP 18.8%(P<0.001)。
- 亚组A骨病灶准确率:PSMA SPECT/CT 98.7% vs MDP 82.9%(P<0.001)。
- 亚组B总体病灶灵敏度:PSMA SPECT/CT 93.1% vs PSMA PET/CT 96.6%(P=1.000),非劣效Δ=10%。
临床怎么用
- 在前列腺癌骨病灶评估中,[99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT可减少MDP常见的假阳性。
- 在PSMA PET/CT不可及时,该SPECT/CT可作为灵敏度相当的PSMA显像替代选择。
局限性
- 单中心回顾性设计。
- 亚组B样本量小(n=13)且Gold−病灶少,特异性估计受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [99mTc]Tc-HYNIC-PSMA-XL-2 is a PSMA-targeted SPECT tracer with low urinary bladder activity. We assessed its real-world performance in paired head-to-head comparisons versus [99mTc]Tc-MDP and PSMA PET/CT. METHODS: Single-center retrospective study (Jan 1, 2020–Nov 25, 2025) using within-patient paired scans within 30 days. Subcohort A included [99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT vs. [99mTc]Tc-MDP (n = 38). Subcohort B included [99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT vs. PSMA PET/CT (either [68Ga]Ga-PSMA-11 or [18F]PSMA-1007; n = 13). Lesions were classified by a composite reference standard (Gold+/Gold−). Sensitivity/specificity/accuracy were compared with McNemar’s test; non-inferiority versus PET/CT used Δ = 10% (sensitivity and accuracy). RESULTS: In Subcohort A, 76 bone lesions were evaluated (Gold + 60, Gold − 16). Sensitivity was high for both modalities (MDP 100.0% vs. [99mTc]Tc-HYNIC-PSMA-XL-2 98.3%; P = 1.000). [99mTc]Tc-HYNIC-PSMA-XL-2 showed higher specificity (100.0% vs. 18.8%; P < 0.001) and accuracy (98.7% vs. 82.9%; P < 0.001), with fewer false positives (FP 0 vs. 13). In Subcohort B, overall lesion sensitivity was comparable (93.1% vs. 96.6%; P = 1.000), and non-inferiority criteria were met (Δ = 10%); specificity estimates were limited by few Gold− lesions. CONCLUSION: [99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT reduces false-positive bone findings versus [99mTc]Tc-MDP and meets prespecified non-inferiority criteria versus PSMA PET/CT, supporting its potential as an accessible PSMA imaging option.
引用
- Bian L, Liu C, Xu X, et al. Clinical performance of [99mTc]Tc-HYNIC-PSMA-XL-2 SPECT/CT in prostate cancer: paired head-to-head comparisons with [99mTc]Tc-MDP and PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2026. PMID: 41686218. doi:10.1007/s00259-026-07811-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。